Haemonetics Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher A. Simon
- Full Time Employees
- 3,009
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 125 Summer Street Boston MA United States of America 02110
- IPO Date
- May 10, 1991
- CIK
- 0000313143
- Website
- haemonetics.com
- Similar Companies
- Business
- Haemonetics Corporation (NYSE: HAE) develops, manufactures and markets innovative medical technologies and software solutions that address blood management needs; the company offers automated blood collection and processing systems including the NexSys PCS plasmapheresis platform with Persona technology and Express Plus software, cell salvage autotransfusion devices such as the Cell Saver Elite+ with Intelligent Control, hemostasis analyzers like the TEG 6s with Global Hemostasis-HN cartridge, vascular closure systems including the VASCADE portfolio, interventional guidewires from SavvyWire and OptoWire via OpSens, esophageal cooling devices such as ensoETM from Attune Medical, and blood management software encompassing BloodTrack HaemoBank, SafeTrace Tx transfusion management and NexLynk DMS; Haemonetics serves hospitals, plasma collection centers, blood banks and surgical suites with products that enhance patient outcomes, improve operational efficiency and ensure blood safety. Founded in 1971 and headquartered in Boston, Massachusetts, the company maintains global operations across North America, Europe, Asia-Pacific and Latin America, with manufacturing facilities including sites in the United States and Mexico. In recent developments, Haemonetics announced in December 2024 a binding agreement to divest its Transfusion Medicine whole blood business—including blood collection, processing, filtration and transfusion solutions—to GVS S.p.A. for up to $67.1 million with closure expected in Q1 2025; the company completed acquisitions of Attune Medical in 2024 adding the ensoETM device, launched the TEG 6s Global Hemostasis-HN cartridge and earned CE Mark for SavvyWire in 2024, acquired OpSens Inc. in 2023 for guidewire technologies, and secured FDA clearances and international approvals for plasma and vascular products in 2023.
Company News
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Is Haemonetics Corp (HAE) Overvalued After 17.5% Rally? GF Value Says Overvalued
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue
PAHC vs. HAE: Which Stock Is the Better Value Option?
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
Analyzing Haemonetics (NYSE:HAE) and Femasys (NASDAQ:FEMY)
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy?
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
GEHC vs. HAE: Which Stock Is the Better Value Option?
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve